Key result
BNT162b2 mRNA Covid-19 vaccine is linked to severe rhabdomyolysis without myocarditis in an adolescent.
Case Report (n=1)
No
This case report highlights the potential for rhabdomyolysis without myocarditis as a rare adverse event following BNT162b2 mRNA Covid-19 vaccination in adolescents.
Post-vaccine rhabdomyolysis without myocarditis may occur in adolescents; hypothesis-generating and should not yet change practice.
Pfizer-BioNTech COVID-19 (BNT162b2) conferred a high level of protection against Covid-19 with a proven short-term safety profile. Although cases of vaccine-associated myopericarditis have been reported, the existence of rhabdomyolysis without myocarditis has not yet been published. A 16-year-old, healthy male patient, who did not use any herbal or illegal drugs before, was admitted with muscle pain that developed after the second dose of BNT162b2 vaccine. Cardiac examination and heart enzymes were normal and the patient had significantly higher creatinine kinase levels. The patient, whose enzymes returned to normal with only force hydration therapy, recovered without complications. Reporting the side effects of the vaccine, which has a short history of application to large populations, is of vital importance in the conduct of vaccine development studies and in identifying the risky group in terms of side effects.
No takes yet. Share an insight, caveat, or question.
Sütçü et al. (2022) conducted a case report in Rhabdomyolysis (n=1). BNT162b2 mRNA Covid-19 vaccine was evaluated on Development of rhabdomyolysis and recovery. A 16-year-old male developed severe rhabdomyolysis without myocarditis 10 days after receiving the second dose of the BNT162b2 mRNA Covid-19 vaccine, which resolved with hydration therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: